Darnytsia Registered a Medicine for the Treatment of Severe Traumatic Brain Injuries in Georgia

Darnytsia Pharmaceutical Company has successfully registered  a medicine used for the treatment of severe traumatic brain injuries in Georgia.

This is another step towards the expansion of the company's international presence and ensuring access of patients to effective Ukrainian medicines.

Although Georgia is not a EU member, its legal requirements for the registration of medicinal products are oriented towards the standards of the European Union. High requirements to the quality and efficiency of medicines in this country confirm that Ukrainian medicines meet international standards.

As a reminder, in 2024 the company received registration of 10 medicinal products outside Ukraine and entered 6 new markets, including the EU countries, Bosnia and Herzegovina, Israel, New Zealand and Malaysia. 

In total, Darnytsia medicinal products are available in more than 20 countries.

"The registration of our medicinal drug in Georgia is an important achievement for the company. We are proud to offer patients in Georgia an effective solution for the treatment of severe traumatic brain injuries. This is yet another proof of our commitment to scientific development, international quality standards and expanding access to quality and effective medicines,"  says Anna Pavliuk-Havrylova, Head of the Department of International Registration and Market Expansion at Darnytsia Pharmaceutical Company.